Product Description | Glucagon (19-29), aka miniglucagon, the C-terminal (19-29) fragment inhibited both the Ca2+ activated and Mg2+ dependent ATPase activity and Ca2+ transport in liver plasma membranes with an efficiency 1000-fold higher than that of glucagon. It is likely to be the active peptide involved in the inhibition of the liver Ca2+ pump. |
Scientific Background | Glucagon (19 - 29), bovine, human, porcine is a synthetic research peptide in the glucagon research peptide family. Glucagon is a 29-residue peptide hormone and the endogenous ligand of the glucagon receptor, a class B G-protein-coupled receptor. Structural work with glucagon analogs supports the two-domain recognition model in which peptide contacts with the extracellular and transmembrane receptor regions cooperate in ligand binding and activation. Truncated, substituted, amidated, and labeled glucagon peptides are useful for defining receptor-contact residues and distinguishing binding from signaling. |
Experimental Notes | For fragments, substituted analogs, labeled peptides, stereochemical variants, or terminally modified forms, experimental behavior should be evaluated for the exact construct rather than assumed to match the native parent peptide. Sequence-dependent solubility, aggregation, adsorption, oxidation, and stability should be considered when establishing reconstitution, storage, and assay conditions. |
